Agenus Inc.
AGEN
NASDAQ·Healthcare·Biotechnology·Mkt cap $343.1M
$8.24
▲ 0.00%
P/E
3.03
Mkt Cap
$343.1M
52-Wk Range
$2.71–$8.85
52-Week Range
$2.71 - $8.85
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 93.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Retrocyte Display antibody expression platform
- Strategic partnerships with major pharmaceutical companies (Merck, Incyte, Gilead)
- QS-21 Stimulon adjuvant technology with clinical validation
- Diversified clinical-stage pipeline reducing development risk
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Clinical trial progression of Balstilimab and next-generation immunotherapy candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+162.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying AGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of $0.06 vs $0.05 consensus (+33.3% surprise). Revenue of $34.5M vs $34.0M expected (+1.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+33.3%
Revenue trend · last 8Q
—
—
-14%
+9%
+20%
+27%
+40%
+34%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$25.1M
$26.8M
$24.1M
$25.7M
$30.2M
$34.2M
$33.7M
$34.5M
Margins · last 8Q
Gross
0.0%
Operating
32.7%
Profit
0.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 11, 2026
vs Industry
How AGEN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related